Search

Copyright of Chinese Journal of Immunology is the property of Medical Periodical Society of Jilin and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To probe into the efficacy and safety of paclitaxel combined with carboplatin in treatment of advanced and recurrent cervical cancer. METHODS: 100 patients with advanced and recurrent cervical cancer admitted into Hubei Provence Cucheng County People’s Hospital from May 2012 to May 2015 where selected to be divided into observation group and control group via the random double chromosphere table, with 50 cases in each. The control group were treated with paclitaxel combined with cisplatin, while the observation group received paclitaxel combined with carboplatin. The total effective rate, disease control rate and overall survival rate of two groups were compared, and adverse drug reactions were recorded. RESULTS; The total effective rate, disease control rate in two groups without any statistically significant difference between two groups ( P > 0. 05). There was no statistically significant difference between two groups in III-IV degree of bone marrow suppression and incidence of renal toxicity(P >0.05 ). Yet the incidence of gastrointestinal reaction of III-IV degree of patients in observation group was significantly lower than that of control group, with statistically significant difference (P < 0. 05 ). According to the results of follow-up visit, there was no statistical significance between two groups in 5-year survival rate and overall survival rate of two groups( P >0. 05 ). CONCLUSIONS: The efficacy of paclitaxel combined with cisplatin in treatment of advanced and recurrent cervical cancer is comparable to that of paclitaxel combined with carboplatin, yet the former regimen has few adverse drug reactions with high safety. [ABSTRACT FROM AUTHOR]